MucoLife Therapeutics was born from a shared passion to revolutionize the treatment of mucus obstruction in chronic pulmonary diseases that affect millions across the globe. Founded by researcher and visionary entrepreneurs from the Mucin Biology Groups at University of Gothenburg, we leverage 40 years of groundbreaking research in mucin biology to bring benefit for the patients.

We are developing a pipeline of innovative medications targeting obstructive mucus accumulation in COPD and other chronic pulmonary diseases.

Together with our investors, we are dedicated to transform healthcare and improving the lives of millions.